Biotech Archives - Page 138 of 795

3 minute read

Aprea Therapeutics Provided A Corporate Update Highlighting Recent Developments And Plans For Advancement Of Its Pipeline Of DNA Damage Response Anti-Cancer Agents In 2024

January 4, 5:12 PM

Update on Phase 1/2a Ongoing Trial of ATR Program, ATRN-119Enrollment of patients continues in the dose escalation portion of the Phase 1/2a clinical trial (study AR-276-01) evaluating ATRN-119 in patients with advanced

APRE

8 minute read

Allogene Therapeutics Announces 2024 Platform Vision To Redefine The Future Of CAR T Led By ALPHA3, the Industry’s First Pivotal Trial For Frontline Consolidation In Large B-Cell Lymphoma

By Benzinga Newsdesk

January 4, 5:09 PM

Four Core Programs Leverage Unique Attributes in Product Development and Trial Design to Demonstrate the Unmatched Potential of an Allogeneic CAR TLarge B-Cell Lymphoma (LBCL): Groundbreaking ALPHA3 Trial has Potential

ALLO

6 minute read

Vaxcyte Provides Clinical And Regulatory Progress Update On Potential Best-In-Class Pneumococcal Conjugate Vaccine Franchise

By Benzinga Newsdesk

January 4, 5:08 PM

-- Company Doses First Participants in Phase 2 Portion of Ongoing VAX-31 Phase 1/2 Study in Adults Following Independent Review of Phase 1 Safety and Tolerability Data; Topline Safety, Tolerability and

PCVX

3 minute read

Intellia Therapeutics Highlights Its 3-Year Strategic Priorities And Anticipated 2024 Key Milestones; Ended 2023 In A Strong Financial Position With Approximately $1B In Cash; Cash Runway Extended Into Mid-2026

By Benzinga Newsdesk

January 4, 5:02 PM

Core priorities through 2026 include completion of Phase 3 study and BLA submission for NTLA-2002, completion of patient enrollment in the pivotal study of NTLA-2001, clinical validation of modular in vivo gene insertion

NTLA

2 minute read

Nuwellis Receives FDA Clearance For An Additional Dual Lumen Extended Length Peripheral Catheter

By Benzinga Newsdesk

January 4, 4:11 PM

Nuwellis, Inc. (NASDAQ:NUWE), a medical technology company focused on transforming the lives of people with fluid overload, today announced it has received U.S. Food and Drug Administration (FDA) clearance for its

NUWE

2 minute read

Atai Life Sciences Shows Positive Results In Phase 1 Clinical Study For PTSD Treatment

By Lara Goldstein

January 4, 3:31 PM

Biopharma company Atai Life Sciences (NASDAQ: ATAI) shared positive results from a Phase 1 clinical study on MDMA R-enantiomer, EMP-01, under development for the potential treatment of PTSD.

ATAI

1 minute read

Blood Cancer Player Arcellx Finds Place On Analyst Conviction List – Potential Room For Growth In 2024

By Vandana Singh

January 4, 3:08 PM

Needham analyst forecasts positive outlook for Arcellx Inc (ACLX) in 2024, citing potential from pivotal interim readout & strong data from Phase I study, raising price target & adding to Conviction List.

ACLX

1 minute read

Eli Lilly Launches Website To Help Patients With Home Delivery Options For Weight Loss Medicines

By Vandana Singh

January 4, 1:21 PM

Eli Lilly announced a new website allowing patients to get a weight loss drug prescription through a telehealth provider, with disease management resources, home delivery of medicines.

LLY

4 minute read

“DEA Confirms That Psychedelic Mushroom Spores Are Federally Legal Prior To Germination” – Marijuana Moment

By Benzinga Newsdesk

January 4, 12:41 PM

A top Drug Enforcement Administration (DEA) has affirmed that spores that produce so-called magic mushrooms are not, on their own, federally prohibited.DEA's Drug & Chemical Evaluation Section Chief Terrence Boos was

CMPS

2 minute read

Bayer Study On Parkinson’s Disease Gene Therapy Succeeds In Early-Stage Trial

By Vandana Singh

January 4, 11:58 AM

Bayer completed an 18-month data collection in the Phase Ib trial for a gene therapy for treating patients with Parkinson's.

BAYRY